A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
Michael Friedlander, Kenneth C Hancock, Danny Rischin, Mark J Messing, Claude A Stringer, Gemma M Matthys, Bo Ma, Jeffrey P Hodge, Joanne J Lager
Gynecologic Oncology | ACADEMIC PRESS INC ELSEVIER SCIENCE | Published : 2010
M. Friedlander received an honorarium from GlaxoSmithKline for speaking at an investigators' meeting in June 2007 (beyond the 24-month ACCME definition of a relevant financial relationship requiring disclosure), and reports no other relevant financial relationships. D. Rischin received funding from GlaxoSmithKline for the trial reported in this manuscript. B. Ma and J.P. Hodge are employed by GlaxoSmithKline and own company stock. G.M. Matthys is also employed by GlaxoSmithKline, but reports no stock ownership. J.J. Lager reports employment relationships with GlaxoSmithKline (during authorship) and Sanofi-aventis. Authors Hancock, Messing, and Stringer report no potential conflict of interest.Financial support for this study and medical editorial assistance was provided by GlaxoSmithKline Pharmaceuticals, Philadelphia, Pennsylvania. The authors acknowledge Jerome Sah, PhD, ProEd Communications, Inc.(R), for his medical editorial assistance with this manuscript. The authors also acknowledge additional principal investigators who participated in this study: Dr. Benedict Benigno of Southeastern Gynecologic Oncology, Atlanta, GA, USA; Dr. Erik Koon of Texas Oncology, Dallas, TX, USA; Dr. Siew Eng Lim of the National University Hospital, Singapore; Dr. Eng Hseon Tay of Kandang Kerbau Women and Children's Hospital, Singapore; Dr. Michael G. Teneriello of Texas Oncology, Austin, TX, USA; and Dr. Paul Vasey of Royal Brisbane and Women's Hospital, Herston, QLD, Australia.